Merck & Co., Inc. (MRK)
Deutsche Bank Has 4 Sizzling ‘Fresh Money' Dividend Stock Picks for Q3
24/7 Insights With the S&P 500 up 15% year-to-date, a correction could be coming in the third quarter.
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
Merck (MRK) reachead $126.04 at the closing of the latest trading day, reflecting a +0.21% change compared to its last close.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
What's Next For Elanco Stock After Its Recent 20% Drop?
The stock price of Elanco (NYSE: ELAN), an animal health products company, saw a 20% fall on Thursday, June 27, after the company announced a delay in expected approval of two drugs. In comparison, Merck stock (NYSE: MRK), which also has an animal health business, was down 1%.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles".
China grants licence to Merck's KEYTRUDA for stomach cancer treatment
China's National Drug Administration has granted Merck's KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
Merck & Co's Frankfurt-listed shares fell 10% on Tuesday morning after the pharmaceutical giant said it had decided to call off a Phase III trial of its cancer drug Xevinapant, in an unexpected turn that threatens to undermine confidence in the company's research abilities.
Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know
Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.
